ArticleGut and liver2022

Risk of Hepatitis B Virus (HBV) Reactivation in Patients with Immune-Mediated Inflammatory Diseases Receiving Biologics: Focus on the Timing of Biologics after Anti-HBV Treatment.

Soo Min Ahn et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.